abstract: CONCLUSIONS: For extracranial @entity2 of the head and neck (HNAVMs), in which the nidus was accessible via the percutaneous route, @entity1 sclerotherapy was a feasible and safe first-line treatment, although successful outcomes were obtained for only about half of the subjects. For other HNAVMs, surgical excision with embolization may be the best choice of treatment. OBJECTIVE: To suggest a treatment protocol for @entity0 with HNAVMs by comparing the treatment outcomes and complications of @entity1 sclerotherapy with those of surgical excision combined with embolization. MATERIAL AND METHODS: Twenty @entity0 who had been diagnosed with HNAVM and treated between 1995 and 2002 were retrospectively reviewed. @entity1 sclerotherapy, surgical excision and embolization were used as treatments, either alone or in various combinations. The treatment outcomes and complications with the different modalities were analyzed. RESULTS: @entity1 sclerotherapy was used for 12 cases, with a success rate of 50.0% and a permanent complication rate of 8.3%. Surgical excision combined with embolization was used for 13 @entity0 . Although all @entity0 achieved successful resolution of their HNAVM after surgical excision, 15.4% suffered from permanent complications. In total, 16/20 @entity0 (80.0%) eventually achieved a > or = 75% reduction in the size of their lesions.

title: Treatment for extracranial XXXX of the head and neck.

answer: @entity2


abstract: Despite advances in the detection and treatment of @entity1 , the prognosis for @entity0 with @entity1 is poor, partly as a result of recurrences. We retrospectively analyzed the relationship between recurrence and survival in @entity0 with @entity3 ( @entity3 ), and the promoter methylation of @entity2 , @entity4 , @entity5 , H-cadherin, and RARbeta2 genes to identify a prognostic molecular marker associated with the recurrence of @entity3 . Methylation status from 335 paraffin blocks was determined by methylation-specific PCR. Of the 335 @entity3 samples, promoter methylation was detected in 35% for @entity2 , 39% for RARbeta2, 42% for H-cadherin, 7% for @entity4 , and 21% for @entity5 . Recurrence was observed in 39% (132 of 335) of the @entity0 . Recurrence was significantly associated with histology (P = 0.001) and pathologic stage (P = 0.009). Hypermethylation of any single gene was not associated with recurrence in @entity0 . However, cohypermethylation of @entity2 and @entity5 genes in stage I NSCLCs was associated with an increased risk of recurrence [odds ratio, 6.43; 95% confidence interval (CI), 1.04-20.19; P = 0.02] and poor recurrence-free survival after surgery (hazard ratio, 2.03; 95% CI, 1.09-6.23; P = 0.02). In addition, their survival after recurrence was also 4.62 times poorer (95% CI, 1.27-16.48; P = 0.005) than for those without cohypermethylation of both genes. In conclusion, the present study suggests that cohypermethylation of @entity2 and @entity5 genes in @entity0 with stage I @entity3 may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease.

title: Cohypermethylation of @entity2 and @entity5 promoters as a prognostic factor of recurrence in surgically resected stage I XXXX .

answer: @entity3


abstract: Despite advances in the detection and treatment of @entity1 , the prognosis for @entity0 with @entity1 is poor, partly as a result of recurrences. We retrospectively analyzed the relationship between recurrence and survival in @entity0 with @entity3 ( @entity3 ), and the promoter methylation of @entity2 , @entity4 , @entity5 , H-cadherin, and RARbeta2 genes to identify a prognostic molecular marker associated with the recurrence of @entity3 . Methylation status from 335 paraffin blocks was determined by methylation-specific PCR. Of the 335 @entity3 samples, promoter methylation was detected in 35% for @entity2 , 39% for RARbeta2, 42% for H-cadherin, 7% for @entity4 , and 21% for @entity5 . Recurrence was observed in 39% (132 of 335) of the @entity0 . Recurrence was significantly associated with histology (P = 0.001) and pathologic stage (P = 0.009). Hypermethylation of any single gene was not associated with recurrence in @entity0 . However, cohypermethylation of @entity2 and @entity5 genes in stage I NSCLCs was associated with an increased risk of recurrence [odds ratio, 6.43; 95% confidence interval (CI), 1.04-20.19; P = 0.02] and poor recurrence-free survival after surgery (hazard ratio, 2.03; 95% CI, 1.09-6.23; P = 0.02). In addition, their survival after recurrence was also 4.62 times poorer (95% CI, 1.27-16.48; P = 0.005) than for those without cohypermethylation of both genes. In conclusion, the present study suggests that cohypermethylation of @entity2 and @entity5 genes in @entity0 with stage I @entity3 may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease.

title: Cohypermethylation of XXXX and @entity5 promoters as a prognostic factor of recurrence in surgically resected stage I @entity3 .

answer: @entity2


abstract: Despite advances in the detection and treatment of @entity1 , the prognosis for @entity0 with @entity1 is poor, partly as a result of recurrences. We retrospectively analyzed the relationship between recurrence and survival in @entity0 with @entity3 ( @entity3 ), and the promoter methylation of @entity2 , @entity4 , @entity5 , H-cadherin, and RARbeta2 genes to identify a prognostic molecular marker associated with the recurrence of @entity3 . Methylation status from 335 paraffin blocks was determined by methylation-specific PCR. Of the 335 @entity3 samples, promoter methylation was detected in 35% for @entity2 , 39% for RARbeta2, 42% for H-cadherin, 7% for @entity4 , and 21% for @entity5 . Recurrence was observed in 39% (132 of 335) of the @entity0 . Recurrence was significantly associated with histology (P = 0.001) and pathologic stage (P = 0.009). Hypermethylation of any single gene was not associated with recurrence in @entity0 . However, cohypermethylation of @entity2 and @entity5 genes in stage I NSCLCs was associated with an increased risk of recurrence [odds ratio, 6.43; 95% confidence interval (CI), 1.04-20.19; P = 0.02] and poor recurrence-free survival after surgery (hazard ratio, 2.03; 95% CI, 1.09-6.23; P = 0.02). In addition, their survival after recurrence was also 4.62 times poorer (95% CI, 1.27-16.48; P = 0.005) than for those without cohypermethylation of both genes. In conclusion, the present study suggests that cohypermethylation of @entity2 and @entity5 genes in @entity0 with stage I @entity3 may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease.

title: Cohypermethylation of @entity2 and XXXX promoters as a prognostic factor of recurrence in surgically resected stage I @entity3 .

answer: @entity5


abstract: 50 @entity0 with @entity3 were seen between September 1983 to March 1988. Their ages ranged from 3 months to 10 years with a mean age of 25 months. Male to Female ratio was 2.3 to 1. The diagnosis of @entity3 was made between the fourth to fifteenth day of illness. Marked @entity4 , raised erythrocyte sedimentation rate, leucocytosis, mild @entity1 and sterile @entity5 were common features. All @entity0 had a normal ECG and chest X-ray. 2D echocardiogram was done in the sub-acute phase of the illness in every @entity0 . Sixteen @entity0 (32%) had @entity2 . Thirteen of these had serial 2D echocardiograms done over a period of more than one year. Twelve had echocardiographic resolution of the coronary lesion within 18 months of follow up. @entity0 with @entity2 were significantly younger. All had full clinical recovery with aspirin therapy. @entity3 afflicts mostly young @entity0 and can present as a diagnostic problem. Coronary artery involvement is common, and except for age, it is not predictable by any clinical or laboratory parameter. Serial echocardiographic examinations are necessary in the management of these @entity0 .

title: XXXX --the Singapore experience.

answer: @entity3


abstract: A study was carried out on 41 cases of early @entity5 over a five year period (1983-1987) based on resected stomach specimens. Males (29) outnumbered females (12) by 2.4:1. Mean age was 63 years (Range 30-80 years), and there was an overwhelming Chinese preponderance (40, 97.6%). The indications for endoscopy were: @entity9 (24, 58.5%), gastro-intestinal @entity7 (14, 34.1%) and follow up of megaloblastic @entity6 (3, 7.4%). The diagnosis of @entity2 was unsuspected at endoscopy in 38 @entity0 and the commonest finding was a chronic @entity8 (35, 85.4%). Most of the lesions were located in the body (24, 58.5%) and along the lesser curvature (36, 87.8%). @entity4 (Type III and combined IIc + III) were the commonest macroscopic lesions. @entity11 was the commonest microscopic type (34, 82.9%). @entity10 was present in 19 (47.3%) and lymph node @entity1 in 4 (9.8%). There was only one death from @entity3 (mortality 2.4%).

title: Early XXXX in Singapore.

answer: @entity5


abstract: Coriander (Coriandrum sativum L.) is grown as a spice crop all over the world. The seeds have been used to treat indigestion, @entity0 , @entity5 and @entity2 in the joints. In the present study, an @entity6 extract of the seeds was investigated for effects on insulin release from the pancreatic beta cells in @entity7 -induced @entity0 @entity1 . Blood samples were drawn from the retro-orbital sinus before and 1.5, 3 and 5 h after administration of the seed extract. Serum @entity4 levels were determined by the @entity4 oxidase method. To determine the insulin releasing activity, after extract treatment the animals were anaesthetized by @entity8 , the pancreas was excised, fixed in 10% @entity3 and embedded in paraffin for sectioning. Pancreatic sections of 5 microm were processed for examination of insulin-releasing activity using an immunocytochemistry kit. The results showed that administration of the @entity6 extract (200 and 250 mg/kg, i.p.) exhibited a significant reduction in serum @entity4 . Administration of @entity7 decreased the number of beta cells with insulin secretory activity in comparison with intact @entity1 , but treatment with the coriander seed extract (200 mg/kg) increased significantly the activity of the beta cells in comparison with the @entity0 control @entity1 . The extract decreased serum @entity4 in @entity7 -induced @entity0 @entity1 and increased insulin release from the beta cells of the pancreas.

title: Effect of coriander seed (Coriandrum sativum L.) XXXX extract on insulin release from pancreatic beta cells in @entity7 -induced @entity0 @entity1 .

answer: @entity6


abstract: Coriander (Coriandrum sativum L.) is grown as a spice crop all over the world. The seeds have been used to treat indigestion, @entity0 , @entity5 and @entity2 in the joints. In the present study, an @entity6 extract of the seeds was investigated for effects on insulin release from the pancreatic beta cells in @entity7 -induced @entity0 @entity1 . Blood samples were drawn from the retro-orbital sinus before and 1.5, 3 and 5 h after administration of the seed extract. Serum @entity4 levels were determined by the @entity4 oxidase method. To determine the insulin releasing activity, after extract treatment the animals were anaesthetized by @entity8 , the pancreas was excised, fixed in 10% @entity3 and embedded in paraffin for sectioning. Pancreatic sections of 5 microm were processed for examination of insulin-releasing activity using an immunocytochemistry kit. The results showed that administration of the @entity6 extract (200 and 250 mg/kg, i.p.) exhibited a significant reduction in serum @entity4 . Administration of @entity7 decreased the number of beta cells with insulin secretory activity in comparison with intact @entity1 , but treatment with the coriander seed extract (200 mg/kg) increased significantly the activity of the beta cells in comparison with the @entity0 control @entity1 . The extract decreased serum @entity4 in @entity7 -induced @entity0 @entity1 and increased insulin release from the beta cells of the pancreas.

title: Effect of coriander seed (Coriandrum sativum L.) @entity6 extract on insulin release from pancreatic beta cells in XXXX -induced @entity0 @entity1 .

answer: @entity7


abstract: Coriander (Coriandrum sativum L.) is grown as a spice crop all over the world. The seeds have been used to treat indigestion, @entity0 , @entity5 and @entity2 in the joints. In the present study, an @entity6 extract of the seeds was investigated for effects on insulin release from the pancreatic beta cells in @entity7 -induced @entity0 @entity1 . Blood samples were drawn from the retro-orbital sinus before and 1.5, 3 and 5 h after administration of the seed extract. Serum @entity4 levels were determined by the @entity4 oxidase method. To determine the insulin releasing activity, after extract treatment the animals were anaesthetized by @entity8 , the pancreas was excised, fixed in 10% @entity3 and embedded in paraffin for sectioning. Pancreatic sections of 5 microm were processed for examination of insulin-releasing activity using an immunocytochemistry kit. The results showed that administration of the @entity6 extract (200 and 250 mg/kg, i.p.) exhibited a significant reduction in serum @entity4 . Administration of @entity7 decreased the number of beta cells with insulin secretory activity in comparison with intact @entity1 , but treatment with the coriander seed extract (200 mg/kg) increased significantly the activity of the beta cells in comparison with the @entity0 control @entity1 . The extract decreased serum @entity4 in @entity7 -induced @entity0 @entity1 and increased insulin release from the beta cells of the pancreas.

title: Effect of coriander seed (Coriandrum sativum L.) @entity6 extract on insulin release from pancreatic beta cells in @entity7 -induced XXXX @entity1 .

answer: @entity0


abstract: Coriander (Coriandrum sativum L.) is grown as a spice crop all over the world. The seeds have been used to treat indigestion, @entity0 , @entity5 and @entity2 in the joints. In the present study, an @entity6 extract of the seeds was investigated for effects on insulin release from the pancreatic beta cells in @entity7 -induced @entity0 @entity1 . Blood samples were drawn from the retro-orbital sinus before and 1.5, 3 and 5 h after administration of the seed extract. Serum @entity4 levels were determined by the @entity4 oxidase method. To determine the insulin releasing activity, after extract treatment the animals were anaesthetized by @entity8 , the pancreas was excised, fixed in 10% @entity3 and embedded in paraffin for sectioning. Pancreatic sections of 5 microm were processed for examination of insulin-releasing activity using an immunocytochemistry kit. The results showed that administration of the @entity6 extract (200 and 250 mg/kg, i.p.) exhibited a significant reduction in serum @entity4 . Administration of @entity7 decreased the number of beta cells with insulin secretory activity in comparison with intact @entity1 , but treatment with the coriander seed extract (200 mg/kg) increased significantly the activity of the beta cells in comparison with the @entity0 control @entity1 . The extract decreased serum @entity4 in @entity7 -induced @entity0 @entity1 and increased insulin release from the beta cells of the pancreas.

title: Effect of coriander seed (Coriandrum sativum L.) @entity6 extract on insulin release from pancreatic beta cells in @entity7 -induced @entity0 XXXX .

answer: @entity1


abstract: @entity0 with @entity1 are known to be impaired at organizing and exploring the visual environment. However, these impairments vary across studies, and the conditions determining whether @entity0 are impaired or not are unclear. We aim to clarify this question by distinguishing different types of visual organization processes. A total of 23 @entity0 and matched controls had to identify 2 identical figures embedded in a global structure made of connectors linking figures by pairs. The 2 targets belonged to either the same perceptual group (linked by a connector) or 2 different pairs (not linked by a connector). In a neutral condition, no connectors were presented. Top-down processes were explored by manipulating the proportion of targets linked or not by a connector in 3 experimental blocks. @entity0 needed the same processing time as controls to extract targets linked by a connector from the global structure. They could also focus on connectors when incited to do so. Impairments were observed for targets that were part of different pairs. Extracting such targets is effortful and time consuming, and both groups were slower in this condition than in the neutral condition. However, @entity0 were slowed less than controls. This paradoxical improvement illustrates the fact that @entity0 do not structure visual elements that are part of a global structure and not automatically bound together. Our results suggest this is due to impaired top-down processes.

title: Visual organization processes in XXXX .

answer: @entity1


abstract: Atrophy of skeletal muscle is due to a @entity2 in protein synthesis and an increase in degradation. Studies in vitro have suggested that activation of the dsRNA-dependent protein kinase ( @entity5 ) may be responsible for these changes in protein synthesis and degradation. In order to evaluate whether this is also applicable to @entity0 the action of a @entity5 inhibitor on the development of @entity4 has been studied in @entity1 bearing the MAC16 @entity0 . Treatment of animals with the @entity5 inhibitor (5 mg kg(-1)) significantly reduced levels of phospho- @entity5 in muscle down to that found in non- @entity0 -bearing @entity1 , and effectively attenuated the @entity2 of body weight, with increased muscle mass, and also inhibited @entity0 growth. There was an increase in protein synthesis in skeletal muscle, which paralleled a decrease in eukaryotic initiation factor 2alpha phosphorylation. Protein degradation rates in skeletal muscle were also significantly decreased, as was proteasome activity levels and expression. Myosin levels were increased up to values found in non- @entity0 -bearing animals. Proteasome expression correlated with a decreased nuclear accumulation of nuclear factor-kappaB (NF-kappaB). The @entity5 inhibitor also significantly inhibited @entity0 growth, although this appeared to be a separate event from the effect on @entity3 . These results suggest that inhibition of the autophosphorylation of @entity5 may represent an appropriate target for the attenuation of @entity3 in @entity0 .

title: Attenuation of XXXX in a @entity1 model of @entity4 by inhibition of the dsRNA-dependent protein kinase.

answer: @entity3


abstract: Atrophy of skeletal muscle is due to a @entity2 in protein synthesis and an increase in degradation. Studies in vitro have suggested that activation of the dsRNA-dependent protein kinase ( @entity5 ) may be responsible for these changes in protein synthesis and degradation. In order to evaluate whether this is also applicable to @entity0 the action of a @entity5 inhibitor on the development of @entity4 has been studied in @entity1 bearing the MAC16 @entity0 . Treatment of animals with the @entity5 inhibitor (5 mg kg(-1)) significantly reduced levels of phospho- @entity5 in muscle down to that found in non- @entity0 -bearing @entity1 , and effectively attenuated the @entity2 of body weight, with increased muscle mass, and also inhibited @entity0 growth. There was an increase in protein synthesis in skeletal muscle, which paralleled a decrease in eukaryotic initiation factor 2alpha phosphorylation. Protein degradation rates in skeletal muscle were also significantly decreased, as was proteasome activity levels and expression. Myosin levels were increased up to values found in non- @entity0 -bearing animals. Proteasome expression correlated with a decreased nuclear accumulation of nuclear factor-kappaB (NF-kappaB). The @entity5 inhibitor also significantly inhibited @entity0 growth, although this appeared to be a separate event from the effect on @entity3 . These results suggest that inhibition of the autophosphorylation of @entity5 may represent an appropriate target for the attenuation of @entity3 in @entity0 .

title: Attenuation of @entity3 in a @entity1 model of XXXX by inhibition of the dsRNA-dependent protein kinase.

answer: @entity4


abstract: Atrophy of skeletal muscle is due to a @entity2 in protein synthesis and an increase in degradation. Studies in vitro have suggested that activation of the dsRNA-dependent protein kinase ( @entity5 ) may be responsible for these changes in protein synthesis and degradation. In order to evaluate whether this is also applicable to @entity0 the action of a @entity5 inhibitor on the development of @entity4 has been studied in @entity1 bearing the MAC16 @entity0 . Treatment of animals with the @entity5 inhibitor (5 mg kg(-1)) significantly reduced levels of phospho- @entity5 in muscle down to that found in non- @entity0 -bearing @entity1 , and effectively attenuated the @entity2 of body weight, with increased muscle mass, and also inhibited @entity0 growth. There was an increase in protein synthesis in skeletal muscle, which paralleled a decrease in eukaryotic initiation factor 2alpha phosphorylation. Protein degradation rates in skeletal muscle were also significantly decreased, as was proteasome activity levels and expression. Myosin levels were increased up to values found in non- @entity0 -bearing animals. Proteasome expression correlated with a decreased nuclear accumulation of nuclear factor-kappaB (NF-kappaB). The @entity5 inhibitor also significantly inhibited @entity0 growth, although this appeared to be a separate event from the effect on @entity3 . These results suggest that inhibition of the autophosphorylation of @entity5 may represent an appropriate target for the attenuation of @entity3 in @entity0 .

title: Attenuation of @entity3 in a XXXX model of @entity4 by inhibition of the dsRNA-dependent protein kinase.

answer: @entity1


abstract: PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity5 ( @entity5 ). Based on excellent results with the chemotherapy-only regimen @entity9 , @entity4 , and @entity8 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity0 AND METHODS: Seventy-two untreated @entity5 @entity0 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity9 25 mg/m(2) IV on days 1 to 3, @entity4 200 mg/m(2) on days 1 to 3, and @entity8 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity0 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity1 ( @entity1 ) -negative complete response (CR), @entity1 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity6 developed in 13% of @entity0 . Major and minor @entity3 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity7 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity5 , with an 82% CR rate and a high proportion of @entity1 -negative CRs (46%). Treatment @entity2 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity7 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

title: Rituximab, @entity9 , @entity4 , and XXXX : a new, highly active chemoimmunotherapy regimen for @entity5 .

answer: @entity8


abstract: PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity5 ( @entity5 ). Based on excellent results with the chemotherapy-only regimen @entity9 , @entity4 , and @entity8 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity0 AND METHODS: Seventy-two untreated @entity5 @entity0 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity9 25 mg/m(2) IV on days 1 to 3, @entity4 200 mg/m(2) on days 1 to 3, and @entity8 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity0 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity1 ( @entity1 ) -negative complete response (CR), @entity1 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity6 developed in 13% of @entity0 . Major and minor @entity3 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity7 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity5 , with an 82% CR rate and a high proportion of @entity1 -negative CRs (46%). Treatment @entity2 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity7 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

title: Rituximab, XXXX , @entity4 , and @entity8 : a new, highly active chemoimmunotherapy regimen for @entity5 .

answer: @entity9


abstract: PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity5 ( @entity5 ). Based on excellent results with the chemotherapy-only regimen @entity9 , @entity4 , and @entity8 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity0 AND METHODS: Seventy-two untreated @entity5 @entity0 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity9 25 mg/m(2) IV on days 1 to 3, @entity4 200 mg/m(2) on days 1 to 3, and @entity8 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity0 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity1 ( @entity1 ) -negative complete response (CR), @entity1 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity6 developed in 13% of @entity0 . Major and minor @entity3 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity7 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity5 , with an 82% CR rate and a high proportion of @entity1 -negative CRs (46%). Treatment @entity2 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity7 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

title: Rituximab, @entity9 , @entity4 , and @entity8 : a new, highly active chemoimmunotherapy regimen for XXXX .

answer: @entity5


abstract: PURPOSE: The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of @entity5 ( @entity5 ). Based on excellent results with the chemotherapy-only regimen @entity9 , @entity4 , and @entity8 (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. @entity0 AND METHODS: Seventy-two untreated @entity5 @entity0 age 70 years or younger received rituximab 500 mg/m(2) on day 1 (375 mg/m(2) the first cycle), @entity9 25 mg/m(2) IV on days 1 to 3, @entity4 200 mg/m(2) on days 1 to 3, and @entity8 6 mg/m(2) IV on day 1, given at 4-week intervals with up to six cycles supported with colony-stimulating factor. @entity0 achieving response received maintenance with rituximab 375 mg/m(2) every 3 months for 2 years. RESULTS: The overall response, @entity1 ( @entity1 ) -negative complete response (CR), @entity1 -positive CR, and partial response rates were 93%, 46%, 36%, and 11%, respectively. Severe @entity6 developed in 13% of @entity0 . Major and minor @entity3 were reported in 8% and 5% of cycles, respectively. Advanced clinical stage, del(17p), or increased serum @entity7 levels correlated with a lower CR rate. CONCLUSION: R-FCM is highly effective in previously untreated @entity5 , with an 82% CR rate and a high proportion of @entity1 -negative CRs (46%). Treatment @entity2 is acceptable. Parameters correlating with a lower response rate were advanced clinical stage, high serum @entity7 levels, and del(17p). Based on these results, R-FCM warrants further investigation in randomized clinical trials.

title: Rituximab, @entity9 , XXXX , and @entity8 : a new, highly active chemoimmunotherapy regimen for @entity5 .

answer: @entity4


abstract: INTRODUCTION: Previously, endovascular treatment of @entity2 related to @entity3 ( @entity5 ) involving arteries measuring less than 2 mm in diameter was limited. To our knowledge, there are no reports in the literature addressing stent placement for treatment of @entity2 in arteries of this size. METHODS: Four @entity0 aged 33 to 80 years (mean 57.5 years) with medically refractory @entity5 underwent angioplasty and stenting of small (<2 mm) distal intracerebral arteries. Vessel location and length of follow-up were anterior cerebral artery (ACA) A1 segment (5 months), @entity4 segment (18 months), middle cerebral artery M1 segment (18 months), and posterior cerebral artery P1 segment (8 months) with vessel calibers ranging from 1.2 to 1.8 mm. Clinical and imaging follow-up ranged from 5 to 18 months. RESULTS: All procedures were successfully performed without complications. Follow-up out to 18 months demonstrated one vessel that went on to occlusion while the other stented vessel segments remained patent. One @entity0 died 8 months after stenting, but the death was not related to @entity1 . The remaining @entity0 experienced resolution of the presenting symptomatology and remained asymptomatic throughout follow-up. CONCLUSION: In this small series, stenoses of distal (<2 mm) cerebral arteries were amenable to treatment using new self-expanding stents. We safely and successfully treated four arteries smaller than 2 mm in diameter with newer self-expanding stents. All @entity0 remained clinically asymptomatic. One stent occluded at 5 months and the others remained patent during follow-up. Longer term clinical follow-up is required to determine the durability and viability of this therapy.

title: Utilization of self-expanding stents in the treatment of XXXX in the distal small cerebral vessels.

answer: @entity3


abstract: @entity2 ( @entity2 ) shunting used in the treatment for @entity3 is associated with several complications. Mechanical failure of shunt is the commonest complication of all. Visceral/bowel perforation is an unusual but serious complication of @entity2 shunting. This article reports our experience in the management of ten @entity0 who had @entity2 Shunt catheter protrusion from anus. This is a retrospective study of ten @entity0 who had @entity2 shunt catheter protrusion from anus, admitted in the department of paediatric surgery between Jan 1996 and Dec 2005. The records of above ten cases were reviewed for their clinical presentation and management, etc. We had performed 398 @entity2 shunt operations in the last 10 years. Two hundred and seventy one (68.09%) @entity2 Shunts were done for congenital @entity3 of which 164 were done in infancy/neonatal period and 107 @entity2 shunts were done in the age group of >1-12 years. One hundred and twenty-seven (31.90%) @entity2 shunt operations were done for @entity0 who had @entity3 as a complication following @entity4 ( @entity4 ). Out of 398 @entity2 shunts, ten @entity0 (2.51%) had protrusion of the distal end of peritoneal catheter from anus without causing/leading to @entity2 . We observed a 08.29% mortality of all @entity2 shunt operations. Protrusion of @entity2 shunt catheter per rectum can occur without producing @entity2 . Formal exploration and localization of entry of @entity2 shunt catheter in bowel is not mandatory. Mini laparotomy and revision of peritoneal part of shunt can be done if there is no @entity1 .

title: Trans-anal protrusion of ventriculo-peritoneal shunt catheter with silent bowel perforation: report of ten cases in XXXX .

answer: @entity0


abstract: 1. The aim of the present study was to examine the distribution of unmyelinated, small-diameter myelinated neuronal @entity1 synthase immunoreactive (nNOS-IR) axons and large-diameter myelinated neuronal @entity1 synthase and @entity3 -immunoreactive (PV-IR) axons in the dorsal funiculus (DF) of sacral (S1-S3) and lumbar (L1-L7) segments of the @entity0 .2. nNOS and PV immunohistochemical methods were used to demonstrate the presence of nNOS-IR and PV-IR in the large-diameter myelinated, presumed to be proprioceptive, axons in the DF along the lumbosacral segments.3. Fiber size and density of nNOS-IR and PV-IR axons were used to compartmentalize the DF into five compartments (CI-CV). The first compartment (CI) localized in the lateralmost part of the DF, containing both unmyelinated and small-diameter myelinated nNOS-IR axons, is homologous with the dorsolateral fasciculus, or Lissauer tract. The second compartment (CII) having similar fiber organization as CI is situated more medially in sacral segments. Rostrally, in lower lumbar segments, CII moves more medially, and at upper lumbar level, CII reaches the dorsomedial angle of the DF and fuses with axons of @entity2 . CIII is the largest in the DF and the only one containing large-diameter myelinated nNOS-IR and PV-IR axons. The largest nNOS-IR and PV-IR axons of CIII (8.0-9.2 mum in diameter), presumed to be stem Ia proprioceptive afferents, are located in the deep portion of the DF close to the dorsal and dorsomedial border of the dorsal horn. The @entity2 compartment varies in shape, appearing first as a small triangular area in S3 and S2 segments, homologous with the Philippe-Gombault triangle. Beginning at S1 level, @entity2 acquires a more elongated shape and is seen throughout the lumbar segments as a narrow band of fibers extending just below the dorsal median septum in approximately upper two-thirds of the DF. The CV is located in the basal part of the DF. In general, CV is poor in nNOS-IR fibers; among them solitary PV-IR fibers are seen.4. The analysis of the control material and the degeneration of the large- and medium-caliber nNOS-IR fibers after unilateral L7 and S1 dorsal rhizotomy confirmed that large-caliber nNOS-IR and and PV-IR axons, presumed to be proprioceptive Ia axons, and their ascending and descending collaterals are present in large number in the DF of the lumbosacral intumescence. However, in the DF of the upper lumbar segments, the decrease in the number of nNOS-IR and PV-IR fibers is quite evident.

title: The distribution of primary XXXX synthase- and @entity3 - immunoreactive afferents in the dorsal funiculus of the lumbosacral spinal cord in a @entity0 .

answer: @entity1


abstract: 1. The aim of the present study was to examine the distribution of unmyelinated, small-diameter myelinated neuronal @entity1 synthase immunoreactive (nNOS-IR) axons and large-diameter myelinated neuronal @entity1 synthase and @entity3 -immunoreactive (PV-IR) axons in the dorsal funiculus (DF) of sacral (S1-S3) and lumbar (L1-L7) segments of the @entity0 .2. nNOS and PV immunohistochemical methods were used to demonstrate the presence of nNOS-IR and PV-IR in the large-diameter myelinated, presumed to be proprioceptive, axons in the DF along the lumbosacral segments.3. Fiber size and density of nNOS-IR and PV-IR axons were used to compartmentalize the DF into five compartments (CI-CV). The first compartment (CI) localized in the lateralmost part of the DF, containing both unmyelinated and small-diameter myelinated nNOS-IR axons, is homologous with the dorsolateral fasciculus, or Lissauer tract. The second compartment (CII) having similar fiber organization as CI is situated more medially in sacral segments. Rostrally, in lower lumbar segments, CII moves more medially, and at upper lumbar level, CII reaches the dorsomedial angle of the DF and fuses with axons of @entity2 . CIII is the largest in the DF and the only one containing large-diameter myelinated nNOS-IR and PV-IR axons. The largest nNOS-IR and PV-IR axons of CIII (8.0-9.2 mum in diameter), presumed to be stem Ia proprioceptive afferents, are located in the deep portion of the DF close to the dorsal and dorsomedial border of the dorsal horn. The @entity2 compartment varies in shape, appearing first as a small triangular area in S3 and S2 segments, homologous with the Philippe-Gombault triangle. Beginning at S1 level, @entity2 acquires a more elongated shape and is seen throughout the lumbar segments as a narrow band of fibers extending just below the dorsal median septum in approximately upper two-thirds of the DF. The CV is located in the basal part of the DF. In general, CV is poor in nNOS-IR fibers; among them solitary PV-IR fibers are seen.4. The analysis of the control material and the degeneration of the large- and medium-caliber nNOS-IR fibers after unilateral L7 and S1 dorsal rhizotomy confirmed that large-caliber nNOS-IR and and PV-IR axons, presumed to be proprioceptive Ia axons, and their ascending and descending collaterals are present in large number in the DF of the lumbosacral intumescence. However, in the DF of the upper lumbar segments, the decrease in the number of nNOS-IR and PV-IR fibers is quite evident.

title: The distribution of primary @entity1 synthase- and XXXX - immunoreactive afferents in the dorsal funiculus of the lumbosacral spinal cord in a @entity0 .

answer: @entity3


abstract: 1. The aim of the present study was to examine the distribution of unmyelinated, small-diameter myelinated neuronal @entity1 synthase immunoreactive (nNOS-IR) axons and large-diameter myelinated neuronal @entity1 synthase and @entity3 -immunoreactive (PV-IR) axons in the dorsal funiculus (DF) of sacral (S1-S3) and lumbar (L1-L7) segments of the @entity0 .2. nNOS and PV immunohistochemical methods were used to demonstrate the presence of nNOS-IR and PV-IR in the large-diameter myelinated, presumed to be proprioceptive, axons in the DF along the lumbosacral segments.3. Fiber size and density of nNOS-IR and PV-IR axons were used to compartmentalize the DF into five compartments (CI-CV). The first compartment (CI) localized in the lateralmost part of the DF, containing both unmyelinated and small-diameter myelinated nNOS-IR axons, is homologous with the dorsolateral fasciculus, or Lissauer tract. The second compartment (CII) having similar fiber organization as CI is situated more medially in sacral segments. Rostrally, in lower lumbar segments, CII moves more medially, and at upper lumbar level, CII reaches the dorsomedial angle of the DF and fuses with axons of @entity2 . CIII is the largest in the DF and the only one containing large-diameter myelinated nNOS-IR and PV-IR axons. The largest nNOS-IR and PV-IR axons of CIII (8.0-9.2 mum in diameter), presumed to be stem Ia proprioceptive afferents, are located in the deep portion of the DF close to the dorsal and dorsomedial border of the dorsal horn. The @entity2 compartment varies in shape, appearing first as a small triangular area in S3 and S2 segments, homologous with the Philippe-Gombault triangle. Beginning at S1 level, @entity2 acquires a more elongated shape and is seen throughout the lumbar segments as a narrow band of fibers extending just below the dorsal median septum in approximately upper two-thirds of the DF. The CV is located in the basal part of the DF. In general, CV is poor in nNOS-IR fibers; among them solitary PV-IR fibers are seen.4. The analysis of the control material and the degeneration of the large- and medium-caliber nNOS-IR fibers after unilateral L7 and S1 dorsal rhizotomy confirmed that large-caliber nNOS-IR and and PV-IR axons, presumed to be proprioceptive Ia axons, and their ascending and descending collaterals are present in large number in the DF of the lumbosacral intumescence. However, in the DF of the upper lumbar segments, the decrease in the number of nNOS-IR and PV-IR fibers is quite evident.

title: The distribution of primary @entity1 synthase- and @entity3 - immunoreactive afferents in the dorsal funiculus of the lumbosacral spinal cord in a XXXX .

answer: @entity0


abstract: INTRODUCTION: Sixty-four @entity3 @entity0 were registered at the Pediatric Allergy and Immunology Department, @entity0 's Hospital, Ain Shams University, Cairo, Egypt. DATA: @entity3 were the most common category (35.9%) followed by combined T- and B-cell @entity3 (29.7%), other well defined @entity3 syndromes (18.7%), @entity1 of phagocyte number, function or both (12.5%), and @entity4 (3.1%). The most frequent disorder was common variable @entity3 (18.7%). The mean age at diagnosis was 29.9 months. The consanguinity rate was 62.5%. Recurrent severe @entity2 were seen in all categories. Fifteen @entity0 died (23.4%) from @entity2 with the highest mortality for combined T- and B-cell @entity3 (15.6%). CONCLUSIONS: @entity4 are not rare in Egyptian @entity0 . The observed frequency of combined T- and B-cell @entity3 in our cohort is relatively higher than other countries. It is a prerequisite to establish a national registry of @entity3 in Egypt.

title: XXXX in Egyptian @entity0 : a single-center study.

answer: @entity4


abstract: INTRODUCTION: Sixty-four @entity3 @entity0 were registered at the Pediatric Allergy and Immunology Department, @entity0 's Hospital, Ain Shams University, Cairo, Egypt. DATA: @entity3 were the most common category (35.9%) followed by combined T- and B-cell @entity3 (29.7%), other well defined @entity3 syndromes (18.7%), @entity1 of phagocyte number, function or both (12.5%), and @entity4 (3.1%). The most frequent disorder was common variable @entity3 (18.7%). The mean age at diagnosis was 29.9 months. The consanguinity rate was 62.5%. Recurrent severe @entity2 were seen in all categories. Fifteen @entity0 died (23.4%) from @entity2 with the highest mortality for combined T- and B-cell @entity3 (15.6%). CONCLUSIONS: @entity4 are not rare in Egyptian @entity0 . The observed frequency of combined T- and B-cell @entity3 in our cohort is relatively higher than other countries. It is a prerequisite to establish a national registry of @entity3 in Egypt.

title: @entity4 in Egyptian XXXX : a single-center study.

answer: @entity0


abstract: Eleven @entity0 (9 months to 5 years of age) with intermittent or constant @entity1 on distant gaze were studied to investigate the effect of part-time occlusion. No @entity0 had constant @entity2 on near fixation. Visual acuity was found to be equal in both eyes. All @entity0 were treated by part-time patching of the non-deviating eye from four to six hours a day and tapered as appropriate. If @entity2 recurred after conversion to a heterophoria, part-time occlusion was reinstated. With occlusion, all @entity0 converted to hetero- or orthophoria, at least temporarily. Mean follow-up (to last visit or surgical intervention) was 22 months (range 3 to 37 months). Three @entity0 (27%) later developed constant @entity2 (mean 28.3 months after beginning occlusion) and underwent surgery. Three @entity0 (27%) became and remain orthophoric without further patching. Part-time occlusion for preschool @entity0 with exodeviations that are predominantly unilateral can postpone surgical intervention and convert @entity2 to orthophoria or @entity2 .

title: The use of part-time occlusion for early onset XXXX .

answer: @entity2


abstract: A 55-year-old @entity0 had @entity2 of 4-month duration. Endoscopy revealed a large polypoidal pedunculated blackish mass located in the lower thoracic esophagus. A barium esophagogram revealed a lower esophageal mass. Computed tomography revealed a large polypoidal esophageal mass without any evidence of local invasion or distant disease. Endoscopic biopsy established the diagnosis of @entity1 . A radical resection of the esophagus with three-field lymph nodal dissection was undertaken. The @entity0 made an uneventful recovery. Histopathology confirmed the diagnosis of @entity1 and positive lymph nodes. Adjuvant chemotherapy was given. He succumbed to systemic recurrence after 69 months.

title: Primary XXXX of the esophagus: long-term survival after radical resection.

answer: @entity1


abstract: SJL @entity1 colonized with @entity3 cells undergo a rapid inflammatory response associated with biological and physiological effects including increased @entity4 production and mutations in spleen DNA. By 2 weeks postcolonization, these changes were accompanied by both up- and down-regulation of a number of plasma proteins. In the experiments reported here, plasma from individual SJL @entity1 was analyzed at several time-points over the 2-week period to determine if there were sets of proteins whose expression varied in concert and thus might serve as early biomarkers for @entity2 . Samples were collected just prior to injection of the RcsX cells and then after 4, 8, and 12 days. Albumin and immunoglobulins were depleted, and the samples were resolved by 1D gel electrophoresis. The gels were cut into 20 slices, and the proteins were digested in-gel with trypsin. The digests were treated with iTRAQ reagents and then analyzed using LC/ @entity0 / @entity0 . The resulting data were processed with two software packages, that is, ProQuant and Spectrum Mill, and then subjected to K-means cluster analysis (K = 4). The four clusters revealed a set of highly up-regulated proteins, a set of progressively up-regulated proteins, a set with no major changes, and a set that declined. The first cluster included @entity6 and serum amyloid A; the second included groups with several functions including protease inhibition, cell motility, and transport. The iTRAQ results for a selection of the up-regulated proteins, including @entity6 , @entity7 , serum amyloid P component, and ceruloplasmin, were confirmed with Western blots. Prominent down-regulated proteins included esterase-1, paraoxonase, and @entity8 . Approximately 50% of the up-regulated proteins are canonical acute phase proteins, while the remainder are regulated by the @entity5 transcription factor.

title: Comparative time-dependent analysis of potential inflammation biomarkers in XXXX @entity1 .

answer: @entity3


abstract: SJL @entity1 colonized with @entity3 cells undergo a rapid inflammatory response associated with biological and physiological effects including increased @entity4 production and mutations in spleen DNA. By 2 weeks postcolonization, these changes were accompanied by both up- and down-regulation of a number of plasma proteins. In the experiments reported here, plasma from individual SJL @entity1 was analyzed at several time-points over the 2-week period to determine if there were sets of proteins whose expression varied in concert and thus might serve as early biomarkers for @entity2 . Samples were collected just prior to injection of the RcsX cells and then after 4, 8, and 12 days. Albumin and immunoglobulins were depleted, and the samples were resolved by 1D gel electrophoresis. The gels were cut into 20 slices, and the proteins were digested in-gel with trypsin. The digests were treated with iTRAQ reagents and then analyzed using LC/ @entity0 / @entity0 . The resulting data were processed with two software packages, that is, ProQuant and Spectrum Mill, and then subjected to K-means cluster analysis (K = 4). The four clusters revealed a set of highly up-regulated proteins, a set of progressively up-regulated proteins, a set with no major changes, and a set that declined. The first cluster included @entity6 and serum amyloid A; the second included groups with several functions including protease inhibition, cell motility, and transport. The iTRAQ results for a selection of the up-regulated proteins, including @entity6 , @entity7 , serum amyloid P component, and ceruloplasmin, were confirmed with Western blots. Prominent down-regulated proteins included esterase-1, paraoxonase, and @entity8 . Approximately 50% of the up-regulated proteins are canonical acute phase proteins, while the remainder are regulated by the @entity5 transcription factor.

title: Comparative time-dependent analysis of potential inflammation biomarkers in @entity3 XXXX .

answer: @entity1


abstract: @entity10 X-160 which lacks catabolite control by @entity1 was isolated from nature (soy moromi mash). Wild-type strains, in @entity5 - @entity1 medium, utilized @entity1 preferentially over @entity5 and showed diauxic growth. With wild-type strain I-13, @entity5 isomerase activity was not induced until @entity1 was consumed from the medium. Strain X-160, however, utilized @entity5 concurrently with @entity1 and did not show diauxic growth. In this strain, @entity5 isomerase was induced even in the presence of @entity1 . @entity1 transport activity in intact cells of strain X-160 was less than 10% of that assayed in strain I-13. Determinations of glycolytic enzymes did not show any difference responsible for the unique behavior of strain X-160, but the rate of @entity3 formation with @entity6 ( @entity7 ) as a @entity9 donor in permeabilized cells was less than 10% of that observed in the wild type. Starved @entity10 I-13 cells contained the glycolytic intermediates @entity8 , @entity11 , and @entity7 ( @entity7 pool). These were consumed concomitantly with @entity1 or @entity2 uptake but were not consumed with @entity5 uptake. The @entity1 transport system in @entity10 was identified as a @entity7 : @entity4 phosphotransferase system on the basis of the substrate specificity of @entity7 pool-starved cells. It is concluded that, in @entity10 , this system is functional as a main @entity1 transport system and that defects in this system may be responsible for the @entity0 of @entity1 -mediated catabolite control.

title: Correlation between @entity0 of catabolite control of XXXX metabolism and a defect in the @entity6 : @entity4 phosphotransferase system in @entity10 .

answer: @entity5


abstract: @entity10 X-160 which lacks catabolite control by @entity1 was isolated from nature (soy moromi mash). Wild-type strains, in @entity5 - @entity1 medium, utilized @entity1 preferentially over @entity5 and showed diauxic growth. With wild-type strain I-13, @entity5 isomerase activity was not induced until @entity1 was consumed from the medium. Strain X-160, however, utilized @entity5 concurrently with @entity1 and did not show diauxic growth. In this strain, @entity5 isomerase was induced even in the presence of @entity1 . @entity1 transport activity in intact cells of strain X-160 was less than 10% of that assayed in strain I-13. Determinations of glycolytic enzymes did not show any difference responsible for the unique behavior of strain X-160, but the rate of @entity3 formation with @entity6 ( @entity7 ) as a @entity9 donor in permeabilized cells was less than 10% of that observed in the wild type. Starved @entity10 I-13 cells contained the glycolytic intermediates @entity8 , @entity11 , and @entity7 ( @entity7 pool). These were consumed concomitantly with @entity1 or @entity2 uptake but were not consumed with @entity5 uptake. The @entity1 transport system in @entity10 was identified as a @entity7 : @entity4 phosphotransferase system on the basis of the substrate specificity of @entity7 pool-starved cells. It is concluded that, in @entity10 , this system is functional as a main @entity1 transport system and that defects in this system may be responsible for the @entity0 of @entity1 -mediated catabolite control.

title: Correlation between XXXX of catabolite control of @entity5 metabolism and a defect in the @entity6 : @entity4 phosphotransferase system in @entity10 .

answer: @entity0


abstract: @entity10 X-160 which lacks catabolite control by @entity1 was isolated from nature (soy moromi mash). Wild-type strains, in @entity5 - @entity1 medium, utilized @entity1 preferentially over @entity5 and showed diauxic growth. With wild-type strain I-13, @entity5 isomerase activity was not induced until @entity1 was consumed from the medium. Strain X-160, however, utilized @entity5 concurrently with @entity1 and did not show diauxic growth. In this strain, @entity5 isomerase was induced even in the presence of @entity1 . @entity1 transport activity in intact cells of strain X-160 was less than 10% of that assayed in strain I-13. Determinations of glycolytic enzymes did not show any difference responsible for the unique behavior of strain X-160, but the rate of @entity3 formation with @entity6 ( @entity7 ) as a @entity9 donor in permeabilized cells was less than 10% of that observed in the wild type. Starved @entity10 I-13 cells contained the glycolytic intermediates @entity8 , @entity11 , and @entity7 ( @entity7 pool). These were consumed concomitantly with @entity1 or @entity2 uptake but were not consumed with @entity5 uptake. The @entity1 transport system in @entity10 was identified as a @entity7 : @entity4 phosphotransferase system on the basis of the substrate specificity of @entity7 pool-starved cells. It is concluded that, in @entity10 , this system is functional as a main @entity1 transport system and that defects in this system may be responsible for the @entity0 of @entity1 -mediated catabolite control.

title: Correlation between @entity0 of catabolite control of @entity5 metabolism and a defect in the @entity6 : XXXX phosphotransferase system in @entity10 .

answer: @entity4


abstract: @entity10 X-160 which lacks catabolite control by @entity1 was isolated from nature (soy moromi mash). Wild-type strains, in @entity5 - @entity1 medium, utilized @entity1 preferentially over @entity5 and showed diauxic growth. With wild-type strain I-13, @entity5 isomerase activity was not induced until @entity1 was consumed from the medium. Strain X-160, however, utilized @entity5 concurrently with @entity1 and did not show diauxic growth. In this strain, @entity5 isomerase was induced even in the presence of @entity1 . @entity1 transport activity in intact cells of strain X-160 was less than 10% of that assayed in strain I-13. Determinations of glycolytic enzymes did not show any difference responsible for the unique behavior of strain X-160, but the rate of @entity3 formation with @entity6 ( @entity7 ) as a @entity9 donor in permeabilized cells was less than 10% of that observed in the wild type. Starved @entity10 I-13 cells contained the glycolytic intermediates @entity8 , @entity11 , and @entity7 ( @entity7 pool). These were consumed concomitantly with @entity1 or @entity2 uptake but were not consumed with @entity5 uptake. The @entity1 transport system in @entity10 was identified as a @entity7 : @entity4 phosphotransferase system on the basis of the substrate specificity of @entity7 pool-starved cells. It is concluded that, in @entity10 , this system is functional as a main @entity1 transport system and that defects in this system may be responsible for the @entity0 of @entity1 -mediated catabolite control.

title: Correlation between @entity0 of catabolite control of @entity5 metabolism and a defect in the XXXX : @entity4 phosphotransferase system in @entity10 .

answer: @entity6


abstract: @entity10 X-160 which lacks catabolite control by @entity1 was isolated from nature (soy moromi mash). Wild-type strains, in @entity5 - @entity1 medium, utilized @entity1 preferentially over @entity5 and showed diauxic growth. With wild-type strain I-13, @entity5 isomerase activity was not induced until @entity1 was consumed from the medium. Strain X-160, however, utilized @entity5 concurrently with @entity1 and did not show diauxic growth. In this strain, @entity5 isomerase was induced even in the presence of @entity1 . @entity1 transport activity in intact cells of strain X-160 was less than 10% of that assayed in strain I-13. Determinations of glycolytic enzymes did not show any difference responsible for the unique behavior of strain X-160, but the rate of @entity3 formation with @entity6 ( @entity7 ) as a @entity9 donor in permeabilized cells was less than 10% of that observed in the wild type. Starved @entity10 I-13 cells contained the glycolytic intermediates @entity8 , @entity11 , and @entity7 ( @entity7 pool). These were consumed concomitantly with @entity1 or @entity2 uptake but were not consumed with @entity5 uptake. The @entity1 transport system in @entity10 was identified as a @entity7 : @entity4 phosphotransferase system on the basis of the substrate specificity of @entity7 pool-starved cells. It is concluded that, in @entity10 , this system is functional as a main @entity1 transport system and that defects in this system may be responsible for the @entity0 of @entity1 -mediated catabolite control.

title: Correlation between @entity0 of catabolite control of @entity5 metabolism and a defect in the @entity6 : @entity4 phosphotransferase system in XXXX .

answer: @entity10


abstract: Insect cell cultures have been extensively utilised for means of production for heterologous proteins and biopesticides. Spodoptera frugiperda (Sf9) and Trichoplusia ni (High Fivetrade mark) cell lines have been widely used for the production of recombinant proteins, thus metabolism of these cell lines have been investigated thoroughly over recent years. The @entity6 zea cell line has potential use for the production of a biopesticide, specifically the @entity6 single-nucleocapsid nucleopolyhedrovirus (HaSNPV). The growth, virus production, nutrient consumption and waste production of this cell line was investigated under serum-free culture conditions, using SF900II and a @entity0 ( @entity0 ). The cell growth (growth rates and population doubling time) was comparable in SF900II and @entity0 , however, lower biomass and cell specific virus yields were obtained in @entity0 . H. zea cells showed a preference for @entity4 over @entity3 , similar to the High Fivetrade mark cells. @entity5 was accumulated to significantly high levels (16 mM) in SF900II, which is an @entity4 and @entity3 rich medium. However, given the absence of @entity4 and @entity3 in the medium ( @entity0 ), H. zea cells adapted and grew well in the absence of these substrates and no accumulation of @entity5 was observed. The adverse effect of @entity5 on H. zea cells is unknown since good production of biologically active HaSNPV was achieved in the presence of high @entity5 levels. H. zea cells showed a preference for maltose even given an abundance supply of free @entity1 . Accumulation of @entity2 was observed in H. zea cell cultures.

title: Growth, viral production and metabolism of a XXXX zea cell line in serum-free culture.

answer: @entity6


abstract: OBJECTIVE: To determine rates of @entity3 and @entity8 and establish the relationship between gonadal hormone levels and sexual function in patients taking antipsychotic treatment for @entity2 or @entity5 . METHOD: We studied 103 @entity0 with @entity2 or @entity5 (mean age = 46.2 (SD = 12.9) years; 51.5% male) from October 2003 through March 2005. Sexual function was assessed using the Sexual Functioning Questionnaire (SFQ) and compared with (1) normal controls (N = 62; mean age = 36.1 (SD = 9.6) years; 55% male) recruited from primary care attendees and (2) sexually dysfunctional controls recruited from a local @entity3 (N = 57; mean age = 39.1 (SD = 10.7) years; 79% male). @entity7 , sex hormone-binding globulin, @entity4 , @entity1 , @entity6 , follicle-stimulating hormone, and luteinizing hormone levels; psychopathology; and side effects were measured. RESULTS: Mean (SD) total SFQ scores were significantly greater in @entity0 ( @entity0 = 9.9 [5.3]; @entity0 = 7.8 [4.9]) compared with normal controls ( @entity0 = 4.1 [2.9]; @entity0 = 4.09 [2.95]), and similar to the scores of @entity3 attendees ( @entity0 = 7.2 [2.9]; @entity0 = 9.9 [4.5]). The odds ratios of @entity0 having @entity3 compared with normal controls were 15.2 for @entity0 and 3.7 for @entity0 . @entity8 was common (in premenopausal @entity0 , 79% showed hypoestrogenism and 92% showed low @entity6 levels, and 28% of @entity0 showed hypotestosteronism). There was no association between total SFQ scores and @entity7 or gonadal hormone levels. CONCLUSION: @entity0 receiving treatment for @entity2 or @entity5 show high rates of @entity3 and @entity8 . Sexual functioning was not related to @entity7 or gonadal hormone levels.

title: Sexual function and gonadal hormones in patients taking antipsychotic treatment for XXXX or @entity5 .

answer: @entity2


abstract: OBJECTIVE: To determine rates of @entity3 and @entity8 and establish the relationship between gonadal hormone levels and sexual function in patients taking antipsychotic treatment for @entity2 or @entity5 . METHOD: We studied 103 @entity0 with @entity2 or @entity5 (mean age = 46.2 (SD = 12.9) years; 51.5% male) from October 2003 through March 2005. Sexual function was assessed using the Sexual Functioning Questionnaire (SFQ) and compared with (1) normal controls (N = 62; mean age = 36.1 (SD = 9.6) years; 55% male) recruited from primary care attendees and (2) sexually dysfunctional controls recruited from a local @entity3 (N = 57; mean age = 39.1 (SD = 10.7) years; 79% male). @entity7 , sex hormone-binding globulin, @entity4 , @entity1 , @entity6 , follicle-stimulating hormone, and luteinizing hormone levels; psychopathology; and side effects were measured. RESULTS: Mean (SD) total SFQ scores were significantly greater in @entity0 ( @entity0 = 9.9 [5.3]; @entity0 = 7.8 [4.9]) compared with normal controls ( @entity0 = 4.1 [2.9]; @entity0 = 4.09 [2.95]), and similar to the scores of @entity3 attendees ( @entity0 = 7.2 [2.9]; @entity0 = 9.9 [4.5]). The odds ratios of @entity0 having @entity3 compared with normal controls were 15.2 for @entity0 and 3.7 for @entity0 . @entity8 was common (in premenopausal @entity0 , 79% showed hypoestrogenism and 92% showed low @entity6 levels, and 28% of @entity0 showed hypotestosteronism). There was no association between total SFQ scores and @entity7 or gonadal hormone levels. CONCLUSION: @entity0 receiving treatment for @entity2 or @entity5 show high rates of @entity3 and @entity8 . Sexual functioning was not related to @entity7 or gonadal hormone levels.

title: Sexual function and gonadal hormones in patients taking antipsychotic treatment for @entity2 or XXXX .

answer: @entity5


abstract: OBJECTIVES: The onset of @entity3 is often triggered by breathlessness in @entity0 with @entity4 ( @entity4 ). It is hypothesized that these are the psychologic consequences of chronic @entity5 . @entity5 might @entity3 . Acupressure has been shown in other studies to produce relaxation. The aim of this study was to determine if it would lessen @entity5 and reduce @entity3 in @entity0 with @entity4 . SUBJECTS AND DESIGN: Subjects diagnosed with @entity4 were chosen from one medical center and three regional hospitals in Taipei, Taiwan. A randomized, block experimental design was used, with subjects and the data collector blinded. Using age, gender, pulmonary function, smoking, and @entity2 use as matching factors, 44 subjects were randomly assigned to either the true acupressure or the sham acupressure groups. The true acupressure group received a program of acupressure using appropriate acupoints that promote relaxation and relieve @entity5 . The sham acupressure group received acupressure using sham acupoints different from the meridians and ganglionic sections of the true acupressure group. Both acupressure programs lasted 4 weeks, with five sessions per week that lasted 16 minutes per session. OUTCOME MEASURES: The Geriatric Depression Scale (GDS) and Dyspnea Visual Analogue Scale (DVAS) were administered prior to the program as a baseline, and again following the completion of the 4-week program. @entity1 saturation and other physiological indicators were measured before and after each session. RESULTS: The results of this study showed that the GDS scores, DVAS scores, @entity1 saturation, and physiological indicators of the true acupressure group were significantly improved, compared to those of the sham acupressure group. CONCLUSIONS: These findings provide health professionals with an evidence-based intervention to use with @entity0 with @entity4 . Applying this acupressure program in clinical practice, communities, and long-term care units may lessen chronic @entity5 and @entity3 in @entity0 with @entity4 .

title: The psychologic consequences of chronic @entity5 in chronic pulmonary obstruction disease: the effects of acupressure on XXXX .

answer: @entity3


abstract: OBJECTIVES: The onset of @entity3 is often triggered by breathlessness in @entity0 with @entity4 ( @entity4 ). It is hypothesized that these are the psychologic consequences of chronic @entity5 . @entity5 might @entity3 . Acupressure has been shown in other studies to produce relaxation. The aim of this study was to determine if it would lessen @entity5 and reduce @entity3 in @entity0 with @entity4 . SUBJECTS AND DESIGN: Subjects diagnosed with @entity4 were chosen from one medical center and three regional hospitals in Taipei, Taiwan. A randomized, block experimental design was used, with subjects and the data collector blinded. Using age, gender, pulmonary function, smoking, and @entity2 use as matching factors, 44 subjects were randomly assigned to either the true acupressure or the sham acupressure groups. The true acupressure group received a program of acupressure using appropriate acupoints that promote relaxation and relieve @entity5 . The sham acupressure group received acupressure using sham acupoints different from the meridians and ganglionic sections of the true acupressure group. Both acupressure programs lasted 4 weeks, with five sessions per week that lasted 16 minutes per session. OUTCOME MEASURES: The Geriatric Depression Scale (GDS) and Dyspnea Visual Analogue Scale (DVAS) were administered prior to the program as a baseline, and again following the completion of the 4-week program. @entity1 saturation and other physiological indicators were measured before and after each session. RESULTS: The results of this study showed that the GDS scores, DVAS scores, @entity1 saturation, and physiological indicators of the true acupressure group were significantly improved, compared to those of the sham acupressure group. CONCLUSIONS: These findings provide health professionals with an evidence-based intervention to use with @entity0 with @entity4 . Applying this acupressure program in clinical practice, communities, and long-term care units may lessen chronic @entity5 and @entity3 in @entity0 with @entity4 .

title: The psychologic consequences of chronic XXXX in chronic pulmonary obstruction disease: the effects of acupressure on @entity3 .

answer: @entity5


abstract: High-altitude climate therapy is a well-established therapeutic option, which improves clinical symptoms in @entity5 . However, little is known about the underlying immunological mechanisms. The study investigates the influence of high-altitude climate therapy on airway @entity1 and cellular components of specific and unspecific immune response. Exhaled NO significantly decreased within 3 weeks of therapy in @entity0 with @entity2 and intrinsic, moderate and severe @entity5 . @entity6 ( @entity6 )-secreting peripheral blood mononuclear cells (PBMC) increased within 3 weeks of therapy in six of 11 @entity0 , whereas transforming growth factor-beta(1)-secreting PBMC remained stable. Furthermore, monocyte activation, assessed by @entity8 expression significantly decreased during therapy. The frequency of @entity10 -expressing T cells decreased, while regulatory T cells (T(reg)) remained stable. @entity4 and @entity9 mRNA expression in CD4(+) T cells did not change, while @entity3 and @entity7 mRNA expression decreased in eight of 10 @entity0 . The current data demonstrate that high-altitude climate therapy reduces local airway @entity1 . Furthermore, monocytes switch towards a tolerogenic phenotype under high-altitude climate therapy. The T(reg)/Th2 ratio increases; however, because of the absence of antigens/allergens, no de novo differentiation of Th2 nor T(reg) cells is observed. The high-altitude climate therapy therefore may form the immunological basis for the endogenous control of allergen-driven diseases.

title: High-altitude climate therapy reduces local airway XXXX and modulates lymphocyte activation.

answer: @entity1


abstract: Gout is a common chronic @entity6 that can lead to significant disability. Gout is one of the few rheumatological conditions that can be diagnosed with certainty, has a known cause and can be cured with appropriate therapy. Hypouricaemic agents reduce @entity5 concentrations through inhibiting @entity5 production ( @entity3 ) or enhancing @entity5 excretion (probenecid, @entity9 ). @entity3 is the most commonly used hypouricaemic agent but at recommended doses often fails to reduce adequately @entity5 concentrations and prevent @entity7 . The use of probenecid is limited by lack of efficacy in @entity2 . In the last few years, new agents in the management of hyperuricaemia and @entity4 have become available. @entity11 , a new @entity8 oxidase inhibitor, is an effective hypouricaemic agent although further data are required for @entity0 with @entity2 and other significant medical conditions. Rasburicase, a recombinant uricase (which catalyses the conversion of @entity5 to the more readily excreted @entity10 ) is available for prevention of @entity1 . However, its repeated use, as would be required in chronic @entity4 , is limited by antigenicity. A less antigenic PEGylated uricase can rapidly reduce serum @entity5 concentrations and promote resorption of tophi. However, further information with regard to the long-term risks and benefits of these agents is required. These agents may ultimately be used in the short term to rapidly deplete urate stores (induction therapy) followed by long-term therapy with an alternative hypouricaemic agent to prevent subsequent accumulation of @entity5 (maintenance therapy).

title: Emerging therapies in the long-term management of hyperuricaemia and XXXX .

answer: @entity4


abstract: OBJECTIVE: To explore the clinical characteristics and speech therapy of 62 @entity0 with @entity6 . METHODS: Peabody Picture Vocabulary Test (PPVT), Gesell development scales (Gesell), Wechsler Intelligence Scale for Preschool @entity0 (WPPSI) and speech test were performed for 62 @entity0 at the ages of 3 to 8 years with @entity6 . PPVT was used to measure receptive vocabulary skills. GESELL and WPPSI were utilized to represent cognitive and non-verbal ability. The speech test was adopted to assess the speech development. The @entity0 received speech therapy and auxiliary oral-motor functional training once or twice a week. Firstly the target sound was identified according to the speech development milestone, then the method of speech localization was used to clarify the correct articulation placement and manner. It was needed to change food character and administer oral-motor functional training for @entity0 with oral @entity1 . RESULTS: The 62 cases with the apical @entity6 were classified into four groups. The combined pattern of the @entity6 was the most common (40 cases, 64.5%), the next was @entity5 (15 cases, 24.2%). The third was @entity4 (4 cases, 6.5%) and the last one was the @entity2 (3 cases, 4.8%). The substitution errors of velar were the most common (95.2%), the next was omission errors (30.6%) and the last was absence of aspiration (12.9%). @entity1 was found in some @entity0 with problems such as @entity3 and head, unstable jaw, weak tongue strength and poor coordination of tongue movement. Some @entity0 had feeding problems such as preference of eating soft food, keeping food in mouths, eating slowly, and poor chewing. After 5 to 18 times of therapy, the effective rate of speech therapy reached 82.3%. CONCLUSION: The lingua-apical @entity6 can be classified into four groups. The combined pattern of the articulation errors is the most common one. Most of the apical sounds are replaced by velar sounds. The speech localization method is very useful in the therapy of apical @entity6 . For @entity0 with feeding problems and oral @entity1 , it is needed to improve food texture and administer oral motor skill training.

title: [Clinical characteristics and speech therapy of XXXX ].

answer: @entity6


abstract: OBJECTIVE: To compare the clinical features of @entity5 ( @entity2 , @entity5 , @entity4 , M protein and skin changes) syndrome @entity0 from Peking Union Medical College Hospital (PUMCH) with those of @entity0 in previous reports. METHODS: Thirty-two @entity0 with @entity5 were identified in PUMCH over the last two decades. The clinical features of these @entity0 were compared with those in other large series from Japan, China, and the United States. RESULTS: The average age at presentation was 45.8 years; 22 were @entity0 . All 32 @entity0 had @entity2 and decreased knee-jerk reflex. @entity5 was present in 31 @entity0 . Nine @entity0 underwent lymph node biopsy and 5 of them were proven to have @entity6 . Twenty-six @entity0 had at least one endocrine abnormality at time of presentation, not including more commonly prevalent @entity1 or @entity3 . Seventy-two percent (18/25) of the @entity0 had a detectable monoclonal protein with serum immunofixation, but only 16.7% (4/24) had positive results with serum protein electrophoresis. Skin changes were documented in 30 @entity0 . In comparison with other series, we found a higher prevalence of @entity5 and papilloedema. The rates of M protein level, however, were similar. CONCLUSIONS: Most features of our series are similar to those from previous foreign series. The prevalence of M protein in our study was similar to that in previous foreign series, but was not as low as reported in previous Chinese studies. Immunofixation and immunohistochemical staining of bone marrow biopsies are probably more sensitive in detecting M protein as compared with serum protein electrophoresis.

title: [A clinical analysis of 32 cases of XXXX ].

answer: @entity5


abstract: BACKGROUND: Enchondroma is the most common @entity1 of the bones of the foot. @entity4 in this area is relatively rare with @entity1 occurring rarely. In contrast to similar @entity1 in the appendicular skeleton, it is difficult to distinguish between these two @entity1 when they occur in the foot. METHODS: We reviewed the medical records and radiographs of all @entity0 with @entity2 and @entity4 arising from @entity2 (secondary @entity4 ) from the radiologic archives at the @entity5 ( @entity5 ) and identified those @entity0 with @entity1 involving the bones of the foot. There were 755 @entity0 with @entity2 of which 34 (4.8%) involved the foot; there were 340 @entity0 with secondary @entity4 and 14 (4.1%) involved the foot. We compared clinical and radiographic features of both these lesions. We also compared interobserver differences not only for diagnosis but also for the presence of scalloping, @entity3 , @entity6 , and mineralized matrix. RESULTS: Size and location were statistically significant variables differentiating the two @entity1 (p = 0.03). @entity2 had a mean size of 2.7 cm(2). Lesions that occurred in the hindfoot and midfoot were more likely to be malignant compared to those in the forefoot. In comparing interobserver reliability, most disagreement occurred regarding the presence or absence of matrix with the examiners concurring only 51% of the time. With regard to diagnosis, the examiners' accuracy was 71% and 80%. Their accuracy increased only to 83% when they agreed. CONCLUSION: Our findings suggest that it is difficult to differentiate @entity2 in the foot. Concern for malignant change is warranted for cartilage @entity7 of the foot if they exceed 5 cm(2), or if they arise in the midfoot or hindfoot. In these cases, we recommend either biopsy or close clinical followup.

title: Differentiating clinical and radiographic features of XXXX in the foot.

answer: @entity2


abstract: Four kindreds with hereditary hypercalcaemia have been investigated. Thirty-seven of 72 subjects examined had hypercalcaemia with an autosomal dominant pattern of inheritance. Hypercalcaemic @entity0 had total serum @entity3 of 2.91 +/- 0.12 mmol l-1. Serum @entity4 ( @entity4 ) was normal while daily urinary @entity3 excretion was subnormal (below 2.5 mmol) in 45%. Comparison with an age-matched group of @entity0 with @entity2 gave a small overlap regarding serum human @entity4 , urinary @entity3 and the ratio between @entity3 clearance and @entity7 clearance. Family screening therefore is of diagnostic importance. Twelve subjects had been subjected to parathyroid surgery before the correct diagnosis was settled, none of the cases had an @entity5 . Three @entity0 became normocalcaemic and the others had persistent hypercalcaemia. One male non-abuser had seven episodes of @entity6 before surgery and none after. The findings in all four kindreds are compatible with @entity8 ( @entity8 ). This @entity1 of unknown aetiology, therefore, also exists in Scandinavia. It is of importance to consider @entity8 in the differential diagnosis of hypercalcaemia, since this disorder usually has a benign prognosis if untreated.

title: XXXX : a study of four kindreds.

answer: @entity8


abstract: Relatively little is known of the details of human leucocyte antigen (HLA) expression and thymocyte selection in @entity0 thymus. In both @entity0 and @entity1 major histocompatibility complex (MHC) molecules have been described which show a highly restricted thymic expression. Such patterns may offer clues about cellular interactions in thymic selection because @entity1 with MHC expression targeted to specific thymic sites show altered T-cell receptor (TCR) repertoire selection. We have analysed @entity0 thymic HLA class II expression, relating the expression pattern to sites of thymocyte apoptosis. While HLA-DQ is poorly expressed by most peripheral antigen-presenting cells (APC), thymus stains strongly for HLA-DQ as well as for HLA-DR. HLA- @entity5 is abundant in medulla but weakly expressed by cortical cells. Class II expression in @entity2 ( @entity2 ) is unusual in several respects: we have previously shown them to be encircled by HLA-DO+ epithelial cells and here further demonstrate that @entity2 are negative for HLA-DR and HLA-DP, but often positive for HLA-DQ and HLA- @entity5 . Transcriptional control of HLA class II products at this site is thus unlike cells that have previously been studied. Apoptotic thymocytes are restricted to the cortex and the corticomedullary junction. However, a minority of apoptotic cells are visible in the medulla, these being found in the HLA-DQ positive @entity2 . The apoptotic thymocytes in @entity2 can be @entity3 + single positive (SP), @entity4 + SP or @entity3 + @entity4 + double-positive (DP). This study thus shows that the @entity2 within @entity0 thymic medulla are noteworthy both for their unusual hierarchy of HLA class II expression and because they are the only medullary site of thymocyte apoptosis. We propose that @entity2 are a site at which mature thymocytes receive activation/tolerization signals from peptides reprocessed from apoptotic cells. The differential HLA transcriptional control at this site may indicate that specific T-cell subpopulations are affected.

title: T-cell apoptosis and differential human leucocyte antigen class II expression in XXXX thymus.

answer: @entity0


abstract: Cells within @entity0 skin are permanently exposed to mechanical stretching. Here we present evidence that alterations in cell shape trigger biochemical signaling via MAP kinases in @entity0 keratinocytes. In an in vitro attempt we demonstrate a fast but transient activation of @entity3 in response to cell stretch. This activation is reversed by preincubation with functional blocking antibodies directed towards @entity1 . As a second member of MAP kinases, stress-activated protein kinase/c-JUN @entity2 -terminal kinase was activated in a slower fashion, peaking at 1 h after the initial stimulus. The delay in signal transmission suggests that @entity3 and stress-activated protein kinase/c-JUN @entity2 -terminal kinase do not share the same signaling pathway. @entity4 was not activated by cell stretching. The contribution of cytoskeletal elements in signal perception and transduction was evaluated by selective disruption of either actin filaments, microtubules, or keratin filaments but showed no clear effect on stretch-induced activation of @entity3 and stress-activated protein kinase/c-JUN @entity2 -terminal kinase. In conclusion we found evidence of a cell-shape-dependent activation of MAP kinases in @entity0 keratinocytes disclosing @entity5 -integrins as putative mechano-transducers. It is likely that alterations of skin mechanics in vivo underlying pathogenic processes like wound formation and healing trigger physiologic responses via the MAP kinase pathway.

title: Signaling of mechanical stretch in XXXX keratinocytes via MAP kinases.

answer: @entity0


abstract: Screening of an arrayed @entity0 genomic P1 artificial chromosome DNA library by means of the polymerase chain reaction with a specific primer pair from the @entity0 type II hair keratin @entity4 yielded two P1 artificial chromosome clones covering approximately 300 kb of genomic DNA. The contig contained six type II hair keratin genes, @entity6 - @entity6 , and four keratin pseudogenes psihHbA-psihHbD. This hair keratin gene domain was flanked by type II epithelial keratins @entity2 /K6hf and K7, respectively. The keratin genes/pseudogene are 5-14 kbp in size with intergenic distances of 5-19 kbp of DNA and do not exhibit a single direction of transcription. With one exception, type II hair keratin genes are organized into nine exons and eight introns, with strictly conserved exon-intron boundaries. The functional hair keratin genes are grouped into two distinct subclusters near the extremities of the hair keratin gene domain. One subcluster encodes the highly related hair keratins @entity6 , @entity5 , and @entity6 ; The second cluster encodes the structurally less related hair keratins @entity1 , @entity3 , and @entity4 . Reverse transcription-polymerase chain reaction shows that all hair keratin genes are expressed in the hair follicle. Pseudogene psihHbD is also transcriptionally expressed, albeit with alterations in splicing and frameshift mutations, leading to premature stop codons in the splice forms analyzed. Evolutionary tree analysis revealed a divergence of the type II hair keratin genes from the epithelial keratins, followed by their segregation into the members of the two subclusters over time. We assume that the approximately 200 kbp DNA domain contains the entire complement of @entity0 type II hair keratin genes.

title: Characterization of a 300 kbp region of XXXX DNA containing the type II hair keratin gene domain.

answer: @entity0


abstract: The sustenance of most solid @entity1 including @entity3 ( @entity3 ) is strongly dependent on the presence of a functioning vascular network. In this study, we examined the acute effects of a @entity1 vascular disrupting agent (VDA), @entity9 ( @entity9 ; @entity9 ), in an orthotopic model of @entity0 HNC. Noninvasive magnetic resonance imaging (MRI) was used to monitor the vascular response of orthotopic FaDu xenografts to VDA therapy. @entity1 showed a marked but heterogeneous pattern of enhancement after contrast agent injection on serial T1-weighted (T1W) MR images. After VDA treatment, @entity8 and T1W MRI revealed evidence of @entity5 and lack of functioning vessels (enhancement) within the @entity1 . Quantitative estimates of relative vascular volume also showed a significant (P < .01) reduction in @entity9 -treated @entity1 24 hours after therapy compared with untreated controls. Histology and immunostaining of untreated orthotopic FaDu @entity1 revealed poorly differentiated @entity6 histology with distinctly visible @entity7 (+) endothelial cells. In sharp contrast, minimal @entity7 staining with irregular endothelial fragments and faint outlines of blood vessels were seen in @entity9 -treated @entity1 sections. @entity7 immunostaining and histology also highlighted the selectivity of vascular damage and tissue @entity2 after VDA therapy with no evidence of @entity4 observed in normal salivary gland, heart, liver, and skeletal muscle tissues. Together, our results demonstrate a potent and selective vascular disruptive activity of @entity9 in an orthotopic HNC model. Further evaluation into its antitumor effects alone and in combination with other agents is warranted.

title: Acute vascular disruption by XXXX in an orthotopic model of @entity0 @entity3 .

answer: @entity9


abstract: The sustenance of most solid @entity1 including @entity3 ( @entity3 ) is strongly dependent on the presence of a functioning vascular network. In this study, we examined the acute effects of a @entity1 vascular disrupting agent (VDA), @entity9 ( @entity9 ; @entity9 ), in an orthotopic model of @entity0 HNC. Noninvasive magnetic resonance imaging (MRI) was used to monitor the vascular response of orthotopic FaDu xenografts to VDA therapy. @entity1 showed a marked but heterogeneous pattern of enhancement after contrast agent injection on serial T1-weighted (T1W) MR images. After VDA treatment, @entity8 and T1W MRI revealed evidence of @entity5 and lack of functioning vessels (enhancement) within the @entity1 . Quantitative estimates of relative vascular volume also showed a significant (P < .01) reduction in @entity9 -treated @entity1 24 hours after therapy compared with untreated controls. Histology and immunostaining of untreated orthotopic FaDu @entity1 revealed poorly differentiated @entity6 histology with distinctly visible @entity7 (+) endothelial cells. In sharp contrast, minimal @entity7 staining with irregular endothelial fragments and faint outlines of blood vessels were seen in @entity9 -treated @entity1 sections. @entity7 immunostaining and histology also highlighted the selectivity of vascular damage and tissue @entity2 after VDA therapy with no evidence of @entity4 observed in normal salivary gland, heart, liver, and skeletal muscle tissues. Together, our results demonstrate a potent and selective vascular disruptive activity of @entity9 in an orthotopic HNC model. Further evaluation into its antitumor effects alone and in combination with other agents is warranted.

title: Acute vascular disruption by @entity9 in an orthotopic model of @entity0 XXXX .

answer: @entity3


abstract: The sustenance of most solid @entity1 including @entity3 ( @entity3 ) is strongly dependent on the presence of a functioning vascular network. In this study, we examined the acute effects of a @entity1 vascular disrupting agent (VDA), @entity9 ( @entity9 ; @entity9 ), in an orthotopic model of @entity0 HNC. Noninvasive magnetic resonance imaging (MRI) was used to monitor the vascular response of orthotopic FaDu xenografts to VDA therapy. @entity1 showed a marked but heterogeneous pattern of enhancement after contrast agent injection on serial T1-weighted (T1W) MR images. After VDA treatment, @entity8 and T1W MRI revealed evidence of @entity5 and lack of functioning vessels (enhancement) within the @entity1 . Quantitative estimates of relative vascular volume also showed a significant (P < .01) reduction in @entity9 -treated @entity1 24 hours after therapy compared with untreated controls. Histology and immunostaining of untreated orthotopic FaDu @entity1 revealed poorly differentiated @entity6 histology with distinctly visible @entity7 (+) endothelial cells. In sharp contrast, minimal @entity7 staining with irregular endothelial fragments and faint outlines of blood vessels were seen in @entity9 -treated @entity1 sections. @entity7 immunostaining and histology also highlighted the selectivity of vascular damage and tissue @entity2 after VDA therapy with no evidence of @entity4 observed in normal salivary gland, heart, liver, and skeletal muscle tissues. Together, our results demonstrate a potent and selective vascular disruptive activity of @entity9 in an orthotopic HNC model. Further evaluation into its antitumor effects alone and in combination with other agents is warranted.

title: Acute vascular disruption by @entity9 in an orthotopic model of XXXX @entity3 .

answer: @entity0


abstract: OBJECTIVE: To investigate whether ghrelin, a novel endogenous ligand of @entity11 ( @entity11 ), was expressed in the thyroid tissues of different @entity5 , and its implication. METHODS: The paraffin-embedded specimens of thyroid tissues from 2000 to 2004 were obtained from 57 @entity0 with different @entity5 , including 5 subacute @entity5 , 8 @entity8 , 7 @entity7 ( @entity9 ), 8 @entity10 , 5 @entity3 , 3 @entity4 , 8 @entity6 , 3 @entity2 , 5 @entity2 and 5 @entity2 cases. The specimens of normal peri-adenoma thyroid tissues served as controls. Immunohistochemical staining was used to detect ghrelin expression. RESULTS: (1) ghrelin expression was undetectable in the thyroid tissues of normal control, subacute @entity5 , @entity8 and @entity9 . (2) ghrelin expression was also undetected in the tissues of @entity10 , @entity3 and @entity4 . (3) ghrelin-positive staining was found in the @entity1 cells of different types of @entity3 . Five cases were positive within 8 cases in @entity6 , 2 cases were positive within 3 cases in @entity2 , 3 cases were positive within 5 cases in @entity2 , 3 cases were positive within 5 cases in @entity2 . CONCLUSION: Ghrelin is expressed in @entity3 , but not in autoimmune or inflammatory @entity5 and benign nodular @entity5 . The results indicate that ghrelin expression may play an important role in the occurrence and development of @entity3 .

title: [Ghrelin expression in the tissues of different XXXX ].

answer: @entity5


abstract: OBJECTIVES: @entity7 as well as @entity5 resistance are considered to be risk factors for the development of @entity2 . This study was aimed at determining whether any relationship between plasma @entity5 and @entity1 levels and total plasma @entity3 (tHcy) concentrations exists in a population based survey performed 10 years apart. DESIGN AND SETTING: A cross-sectional study was undertaken during the years 1986-87 to examine risk factors for @entity0 and for @entity2 ( @entity2 ) in the Jewish population of Jerusalem. Ten years later two groups of individuals were invited for re-examination. SUBJECTS: Two groups of individuals were examined: the first one consisted of nondiabetic subjects (n = 86), who had @entity6 10 years previously (at the first visit), the second group consisted of normoinsulinemic nondiabetic individuals (n = 265) who had initially normal @entity1 and @entity5 levels. MAIN OUTCOME MEASURES: Metabolic, biochemical and anthropomorphic features were determined. Fasting and post load @entity1 , as well as @entity5 concentrations on fasting and 2 h post @entity1 load were measured at the first and second visits. Plasma tHcy and @entity4 were determined only at the second visit. RESULTS: The results demonstrated a significant negative correlation between plasma tHcy levels and @entity5 levels at the second visit. No difference was found in @entity4 levels between these two groups. CONCLUSIONS: In general, @entity6 and @entity7 are both related to an increased incidence of @entity2 . In our population most of the subjects examined had tHcy levels within the normal range and only a few demonstrated very high levels. However, negative association between @entity5 levels and tHcy concentrations was found. Possible explanations for this finding are discussed.

title: Plasma total @entity3 levels in subjects with XXXX .

answer: @entity6


abstract: OBJECTIVES: @entity7 as well as @entity5 resistance are considered to be risk factors for the development of @entity2 . This study was aimed at determining whether any relationship between plasma @entity5 and @entity1 levels and total plasma @entity3 (tHcy) concentrations exists in a population based survey performed 10 years apart. DESIGN AND SETTING: A cross-sectional study was undertaken during the years 1986-87 to examine risk factors for @entity0 and for @entity2 ( @entity2 ) in the Jewish population of Jerusalem. Ten years later two groups of individuals were invited for re-examination. SUBJECTS: Two groups of individuals were examined: the first one consisted of nondiabetic subjects (n = 86), who had @entity6 10 years previously (at the first visit), the second group consisted of normoinsulinemic nondiabetic individuals (n = 265) who had initially normal @entity1 and @entity5 levels. MAIN OUTCOME MEASURES: Metabolic, biochemical and anthropomorphic features were determined. Fasting and post load @entity1 , as well as @entity5 concentrations on fasting and 2 h post @entity1 load were measured at the first and second visits. Plasma tHcy and @entity4 were determined only at the second visit. RESULTS: The results demonstrated a significant negative correlation between plasma tHcy levels and @entity5 levels at the second visit. No difference was found in @entity4 levels between these two groups. CONCLUSIONS: In general, @entity6 and @entity7 are both related to an increased incidence of @entity2 . In our population most of the subjects examined had tHcy levels within the normal range and only a few demonstrated very high levels. However, negative association between @entity5 levels and tHcy concentrations was found. Possible explanations for this finding are discussed.

title: Plasma total XXXX levels in subjects with @entity6 .

answer: @entity3


abstract: @entity0 kidneys subjected to @entity2 in vivo both develop marked increases in the area under a peak resonating in the phosphodiester region on their @entity5 nuclear magnetic resonance spectra. The chemical species responsible for these changes were assessed using physiologic manipulations which altered the concentration of @entity1 in the urine or increased the urine pH. Obstructed kidneys of @entity0 fed a normal diet had a 140 +/- 50% increase in a peak resonating at 3.31 +/- 0.05 ppm after three hours of obstruction (P less than 0.01). Low @entity1 diet which decreased urine @entity1 concentration by 98% virtually eliminated this increase in peak area, where saline diuresis which decreased urine @entity1 concentration by 50% markedly attenuated it. Acute @entity1 loading which doubled urine @entity1 concentration markedly accentuated the increase in peak area. Alkalinizing the urine with @entity4 (changing urine pH from 6.2 +/- 0.2 to 8.0 +/- 0.1) shifted the resonance frequency of this increasing peak from 3.31 +/- 0.06 to 5.45 +/- 0.11 ppm (P less than 0.01). @entity0 fed a normal diet developed increases (57 +/- 15%, P less than 0.05) in a peak resonating at 2.84 +/- 0.03 ppm following 48 hours of @entity3 . @entity0 fed a low @entity1 diet had a comparable increase in the relative area of this peak (46 +/- 16%, P less than 0.05). Alkalinization of the urine did not affect the position or intensity of this peak under conditions of @entity3 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: XXXX nuclear magnetic resonance spectral changes in obstructed or dehydrated kidney.

answer: @entity5


abstract: The establishment of growth polarity in @entity3 cells is a combined function of the cytoplasmic cytoskeleton and the shape of the cell wall inherited from the mother cell. The septum that divides the cylindrical cell into two siblings is formed midway between the growing poles and perpendicularly to the @entity2 that connects them. Since the daughter cells also extend at their ends and form their septa at right angles to the @entity2 , their septal (division) planes lie parallel to those of the mother cell. To gain a better understanding of how this regularity is ensured, we investigated septation in spherical cells that do not inherit morphologically predetermined cell ends to establish poles for growth. We studied four mutants (defining four novel genes), over 95% of whose cells displayed a completely spherical morphology and a @entity1 and showed a random distribution of cytoplasmic microtubules, Tea1p, and F-actin, indicating that the cytoplasmic cytoskeleton was poorly polarized or apolar. Septum positioning was examined by visualizing septa and division scars by calcofluor staining and by the analysis of electron microscopic images. Freeze-substitution, freeze-etching, and scanning electron microscopy were used. We found that the elongated @entity0 is not essential for the determination of a division plane that can separate the postmitotic nuclei. However, it seems to be necessary for the maintenance of the parallel orientation of septa over the generations. In the spherical cells, the division scars and septa usually lie at angles to each other on the cell surface. We hypothesize that the shape of the cell indirectly affects the positioning of the septum by directing the extension of the spindle.

title: Role of cell shape in determination of the division plane in XXXX : random orientation of septa in spherical cells.

answer: @entity3


abstract: A radiation exposure of 1500 R to the Walker 256 @entity1 @entity0 was found to sensitize this @entity0 to the effect of a sublethal dose of endotoxin (Sarratia marcescens lipopolysaccharide) given 2 days later so that complete or almost complete destruction of the @entity0 resulted. Histological. study showed rapidly developing massive @entity2 of @entity0 tissue. Tracer experiments with 131I-labeled antibody to @entity1 fibrin indicated an absence of blood circulation in the treated @entity0 . These results suggest that the lesion may be secondary to @entity3 occurring in the vascular bed of the @entity0 . Apparently identical lesions were also produced by @entity4 and @entity5 , alone or in combination. It is known that even untreated @entity0 are often the site of fibrin deposition. Presumably radiation, by @entity0 cells, enhances the release of coagulation-producing substances into the vascular bed. It is postulated that the effect of subsequent treatment with the drugs listed above is produced by circulatory stasis induced in the @entity0 . This may be associated with Hageman factor activation or release of platelet factor 3.

title: Endotoxin, XXXX , and @entity5 effects on the radiation-sensitized walker 256 @entity1 carcinosarcoma.

answer: @entity4